Use of γH2AX and other biomarkers of double-strand breaks during radiotherapy.

A hormone-DNA repair circuit governs the response to genotoxic insult. Cancer Discov (2013) 1.97

PI3K/Akt/mTOR pathway inhibitors enhance radiosensitivity in radioresistant prostate cancer cells through inducing apoptosis, reducing autophagy, suppressing NHEJ and HR repair pathways. Cell Death Dis (2014) 1.36

Beyond DNA repair: DNA-PK function in cancer. Cancer Discov (2014) 1.16

Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity. Carcinogenesis (2012) 1.10

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. Br J Cancer (2011) 1.08

CD44 is a biomarker associated with human prostate cancer radiation sensitivity. Clin Exp Metastasis (2011) 0.95

Effects of ionizing radiation on biological molecules--mechanisms of damage and emerging methods of detection. Antioxid Redox Signal (2014) 0.94

MyD88 in DNA repair and cancer cell resistance to genotoxic drugs. J Natl Cancer Inst (2013) 0.87

Correlation of dynamic changes in γ-H2AX expression in peripheral blood lymphocytes from head and neck cancer patients with radiation-induced oral mucositis. Radiat Oncol (2013) 0.85

DNA Damage Response Assessments in Human Tumor Samples Provide Functional Biomarkers of Radiosensitivity. Semin Radiat Oncol (2015) 0.84

Biological dosimetry for breast cancer radiotherapy: a comparison of external beam and intraoperative radiotherapy. Springerplus (2014) 0.83

18F-fluorothymidine-pet imaging of glioblastoma multiforme: effects of radiation therapy on radiotracer uptake and molecular biomarker patterns. ScientificWorldJournal (2013) 0.82

A Perspective on Chromosomal Double Strand Break Markers in Mammalian Cells. Jacobs J Radiat Oncol (2015) 0.82

Aldehyde dehydrogenase 3A1 protects airway epithelial cells from cigarette smoke-induced DNA damage and cytotoxicity. Free Radic Biol Med (2013) 0.81

PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases. PLoS One (2014) 0.80

DNA damage in blood lymphocytes in patients after (177)Lu peptide receptor radionuclide therapy. Eur J Nucl Med Mol Imaging (2015) 0.78

Strategies to optimize radiotherapy based on biological responses of tumor and normal tissue. Exp Ther Med (2012) 0.75

Evaluating biomarkers to model cancer risk post cosmic ray exposure. Life Sci Space Res (Amst) (2016) 0.75

Downregulation of Mitochondrial Single Stranded DNA Binding Protein (SSBP1) Induces Mitochondrial Dysfunction and Increases the Radiosensitivity in Non-Small Cell Lung Cancer Cells. J Cancer (2017) 0.75

Chemoradiation with and without surgery in patients with locally advanced squamous cell carcinoma of the esophagus. J Clin Oncol (2005) 5.19

Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol (2009) 4.38

Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 1: epidemiology, environmental predispositions, clinical manifestations, and therapy. Lancet Infect Dis (2002) 1.80

Hyperfractionated accelerated chemoradiation with concurrent fluorouracil-mitomycin is more effective than dose-escalated hyperfractionated accelerated radiation therapy alone in locally advanced head and neck cancer: final results of the radiotherapy cooperative clinical trials group of the German Cancer Society 95-06 Prospective Randomized Trial. J Clin Oncol (2005) 1.69

Value of 18F-fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in non-small-cell lung cancer for prediction of pathologic response and times to relapse after neoadjuvant chemoradiotherapy. Clin Cancer Res (2006) 1.57

Update on Kaposi's sarcoma and other HHV8 associated diseases. Part 2: pathogenesis, Castleman's disease, and pleural effusion lymphoma. Lancet Infect Dis (2002) 1.31

gamma-H2AX foci formation in peripheral blood lymphocytes of tumor patients after local radiotherapy to different sites of the body: dependence on the dose-distribution, irradiated site and time from start of treatment. Int J Radiat Biol (2007) 1.29

Combination of BRAF Inhibitors and Brain Radiotherapy in Patients With Metastatic Melanoma Shows Minimal Acute Toxicity. J Clin Oncol (2013) 1.14

Ductal pancreatic adenocarcinoma. Dtsch Arztebl Int (2014) 1.14

Radiotherapy versus surgery within multimodality protocols for esophageal cancer--a meta-analysis of the randomized trials. Cancer Treat Rev (2011) 1.11

Clinical response to induction chemotherapy predicts local control and long-term survival in multimodal treatment of patients with locally advanced esophageal cancer. J Cancer Res Clin Oncol (2004) 1.07

Prophylactic cranial irradiation in operable stage IIIA non small-cell lung cancer treated with neoadjuvant chemoradiotherapy: results from a German multicenter randomized trial. J Clin Oncol (2007) 1.06

Arginine deiminase and other antiangiogenic agents inhibit unfavorable neuroblastoma growth: potentiation by irradiation. Int J Cancer (2003) 1.01

Erythropoietin restores the anemia-induced reduction in radiosensitivity of experimental human tumors in nude mice. Int J Radiat Oncol Biol Phys (2003) 0.97

Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer. Oncology (2008) 0.95

Novel prognostic scoring system after surgery for Klatskin tumor. Am Surg (2013) 0.94

Selective inactivation of DNA-dependent protein kinase with antisense oligodeoxynucleotides: consequences for the rejoining of radiation-induced DNA double-strand breaks and radiosensitivity of human cancer cell lines. Cancer Res (2002) 0.93

New insights into the molecular pathology of radiation-induced pneumopathy. Radiother Oncol (2011) 0.91

Increased radiation-induced apoptosis and altered cell cycle progression of human lung cancer cell lines by antisense oligodeoxynucleotides targeting p53 and p21(WAF1/CIP1). Cancer Gene Ther (2003) 0.91

Randomized study of postoperative radiotherapy and simultaneous temozolomide without adjuvant chemotherapy for glioblastoma. Strahlenther Onkol (2008) 0.91

International comparison of the German evidence-based S3-guidelines on the diagnosis and multimodal treatment of early and locally advanced gastric cancer, including adenocarcinoma of the lower esophagus. Gastric Cancer (2014) 0.89

10-year long-term survival (LTS) of induction chemotherapy with three cycles cisplatin/paclitaxel followed by concurrent chemoradiation cisplatin/etoposide/45 Gy (1.5 Gy bid) plus surgery in locally advanced non-small-cell lung cancer (NSCLC)-a multicenter phase-II trial (CISTAXOL). Lung Cancer (2013) 0.86

Intensified high-dose chemoradiotherapy with induction chemotherapy in patients with locally advanced non-small-cell lung cancer-safety and toxicity results within a prospective trial. Int J Radiat Oncol Biol Phys (2009) 0.86

Multimodality treatment of stage IIIA and IIIB non-small cell lung cancer. J Thorac Oncol (2007) 0.85

Thorax irradiation triggers a local and systemic accumulation of immunosuppressive CD4+ FoxP3+ regulatory T cells. Radiat Oncol (2014) 0.85

Helical tomotherapy for whole-brain irradiation with integrated boost to multiple brain metastases: evaluation of dose distribution characteristics and comparison with alternative techniques. Int J Radiat Oncol Biol Phys (2013) 0.85

Inhibiting the aurora B kinase potently suppresses repopulation during fractionated irradiation of human lung cancer cell lines. Int J Radiat Oncol Biol Phys (2012) 0.85

Megavoltage computed tomography image guidance with helical tomotherapy in patients with vertebral tumors: analysis of factors influencing interobserver variability. Int J Radiat Oncol Biol Phys (2012) 0.81

Hyperfractionated accelerated radiotherapy versus conventional fractionation both combined with chemotherapy in patients with locally advanced head and neck carcinomas: a retrospective analysis of a monoinstitutional series. Oncology (2009) 0.80

The effects of motion on the dose distribution of proton radiotherapy for prostate cancer. J Appl Clin Med Phys (2012) 0.80

Chemotherapy: Effectiveness of adjuvant chemotherapy for resected NSCLC. Nat Rev Clin Oncol (2010) 0.79

Reduced contribution of thermally-labile sugar lesions to DNA double-strand break formation after exposure to neutrons. Radiat Res (2012) 0.79

Chemoradiation paradigm for the treatment of lung cancer. Nat Clin Pract Oncol (2006) 0.79

Impact of anemia prevention by recombinant human erythropoietin on the sensitivity of xenografted glioblastomas to fractionated irradiation. Strahlenther Onkol (2003) 0.78

Multi-scenario based robust intensity-modulated proton therapy (IMPT) plans can account for set-up errors more effectively in terms of normal tissue sparing than planning target volume (PTV) based intensity-modulated photon plans in the head and neck region. Radiat Oncol (2013) 0.78

Long-term in vivo effects of cisplatin on gamma-H2AX foci signaling in peripheral lymphocytes of tumor patients after irradiation. Clin Cancer Res (2009) 0.77

Morphological and functional evaluation of angiogenesis of a xenografted human sarcoma in nude mice. Lab Anim (2007) 0.77

Surgery in stage III non-small-cell lung cancer. Lancet (2009) 0.76

Prediction of prognosis after trimodal therapy in patients with locally advanced squamous cell carcinoma of the oesophagus. Eur J Cancer (2012) 0.76

Dependence of radiation-induced H2AX phosphorylation on histone methylation: evidence from the chromatin immunoprecipitation assay. Int J Radiat Biol (2015) 0.76

Intraindividual comparison of conventional three-dimensional radiotherapy and intensity modulated radiotherapy in the therapy of locally advanced non-small cell lung cancer a planning study. Strahlenther Onkol (2002) 0.76

Radiotherapy: prophylactic cranial irradiation for small-cell lung cancer. Nat Rev Clin Oncol (2009) 0.75

Long-term survival following radiotherapy and cytarabine chemotherapy for sporadic primary central nervous system lymphoma. Strahlenther Onkol (2003) 0.75

Pudendal nerve block in HDR-brachytherapy patients: do we really need general or regional anesthesia? World J Urol (2012) 0.75

[Surgery and adjuvant therapy in non-small-cell lung carcinoma (NSCLC). (stage I through operable stage IIIA)]. Onkologie (2006) 0.75

Prophylactic cranial irradiation in lung cancer. Curr Treat Options Oncol (2004) 0.75